437 related articles for article (PubMed ID: 26332672)
21. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
[TBL] [Abstract][Full Text] [Related]
22. MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load.
Janes H; Frahm N; DeCamp A; Rolland M; Gabriel E; Wolfson J; Hertz T; Kallas E; Goepfert P; Friedrich DP; Corey L; Mullins JI; McElrath MJ; Gilbert P
PLoS One; 2012; 7(8):e43396. PubMed ID: 22952672
[TBL] [Abstract][Full Text] [Related]
23. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.
Catanzaro AT; Koup RA; Roederer M; Bailer RT; Enama ME; Moodie Z; Gu L; Martin JE; Novik L; Chakrabarti BK; Butman BT; Gall JG; King CR; Andrews CA; Sheets R; Gomez PL; Mascola JR; Nabel GJ; Graham BS;
J Infect Dis; 2006 Dec; 194(12):1638-49. PubMed ID: 17109335
[TBL] [Abstract][Full Text] [Related]
24. Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity.
Gabitzsch ES; Xu Y; Yoshida LH; Balint J; Amalfitano A; Jones FR
Vaccine; 2009 Oct; 27(46):6394-8. PubMed ID: 19559110
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of Semliki Forest virus based self-amplifying RNA expressing Indian HIV-1C genes in mice.
Ajbani SP; Velhal SM; Kadam RB; Patel VV; Bandivdekar AH
Int J Biol Macromol; 2015 Nov; 81():794-802. PubMed ID: 26361864
[TBL] [Abstract][Full Text] [Related]
26. Characterization of transgene expression in adenoviral vector-based HIV-1 vaccine candidates.
Takahashi MN; Rolling JA; Owen KE
Virol J; 2010 Feb; 7():39. PubMed ID: 20163742
[TBL] [Abstract][Full Text] [Related]
27. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.
McElrath MJ; De Rosa SC; Moodie Z; Dubey S; Kierstead L; Janes H; Defawe OD; Carter DK; Hural J; Akondy R; Buchbinder SP; Robertson MN; Mehrotra DV; Self SG; Corey L; Shiver JW; Casimiro DR;
Lancet; 2008 Nov; 372(9653):1894-1905. PubMed ID: 19012957
[TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.
Mothe B; Climent N; Plana M; Rosàs M; Jiménez JL; Muñoz-Fernández MÁ; Puertas MC; Carrillo J; Gonzalez N; León A; Pich J; Arnaiz JA; Gatell JM; Clotet B; Blanco J; Alcamí J; Martinez-Picado J; Alvarez-Fernández C; Sánchez-Palomino S; Guardo AC; Peña J; Benito JM; Rallón N; Gómez CE; Perdiguero B; García-Arriaza J; Esteban M; López Bernaldo de Quirós JC; Brander C; García F;
J Antimicrob Chemother; 2015; 70(6):1833-42. PubMed ID: 25724985
[TBL] [Abstract][Full Text] [Related]
29. Designed recombinant adenovirus type 5 vector induced envelope-specific CD8(+) cytotoxic T lymphocytes and cross-reactive neutralizing antibodies against human immunodeficiency virus type 1.
Ura T; Yoshida A; Xin KQ; Yoshizaki S; Yashima S; Abe S; Mizuguchi H; Okuda K
J Gene Med; 2009 Feb; 11(2):139-49. PubMed ID: 19065543
[TBL] [Abstract][Full Text] [Related]
30. Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses.
Hopkins KL; Laher F; Otwombe K; Churchyard G; Bekker LG; DeRosa S; Nchabeleng M; Mlisana K; Kublin J; Gray G
PLoS One; 2014; 9(8):e103446. PubMed ID: 25090110
[TBL] [Abstract][Full Text] [Related]
31. Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial.
Li JZ; Brumme ZL; Brumme CJ; Wang H; Spritzler J; Robertson MN; Lederman MM; Carrington M; Walker BD; Schooley RT; Kuritzkes DR;
J Infect Dis; 2011 Apr; 203(7):976-83. PubMed ID: 21402549
[TBL] [Abstract][Full Text] [Related]
32. Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T cells with limited breadth of HIV-1 inhibition.
Hayes PJ; Cox JH; Coleman AR; Fernandez N; Bergin PJ; Kopycinski JT; Nitayaphan S; Pitisuttihum P; de Souza M; Duerr A; Morgan C; Gilmour JW
AIDS; 2016 Jul; 30(11):1703-12. PubMed ID: 27088318
[TBL] [Abstract][Full Text] [Related]
33. First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002).
Baden LR; Walsh SR; Seaman MS; Johnson JA; Tucker RP; Kleinjan JA; Gothing JA; Engelson BA; Carey BR; Oza A; Bajimaya S; Peter L; Bleckwehl C; Abbink P; Pau MG; Weijtens M; Kunchai M; Swann EM; Wolff M; Dolin R; Barouch DH
J Infect Dis; 2014 Oct; 210(7):1052-61. PubMed ID: 24719474
[TBL] [Abstract][Full Text] [Related]
34. HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.
Bart PA; Huang Y; Karuna ST; Chappuis S; Gaillard J; Kochar N; Shen X; Allen MA; Ding S; Hural J; Liao HX; Haynes BF; Graham BS; Gilbert PB; McElrath MJ; Montefiori DC; Tomaras GD; Pantaleo G; Frahm N
J Clin Invest; 2014 Nov; 124(11):4843-56. PubMed ID: 25271627
[TBL] [Abstract][Full Text] [Related]
35. Sexual risk behaviors, circumcision status, and preexisting immunity to adenovirus type 5 among men who have sex with men participating in a randomized HIV-1 vaccine efficacy trial: step study.
Koblin BA; Mayer KH; Noonan E; Wang CY; Marmor M; Sanchez J; Brown SJ; Robertson MN; Buchbinder SP
J Acquir Immune Defic Syndr; 2012 Aug; 60(4):405-13. PubMed ID: 22421748
[TBL] [Abstract][Full Text] [Related]
36. A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.
Keefer MC; Gilmour J; Hayes P; Gill D; Kopycinski J; Cheeseman H; Cashin-Cox M; Naarding M; Clark L; Fernandez N; Bunce CA; Hay CM; Welsh S; Komaroff W; Hachaambwa L; Tarragona-Fiol T; Sayeed E; Zachariah D; Ackland J; Loughran K; Barin B; Cormier E; Cox JH; Fast P; Excler JL
PLoS One; 2012; 7(8):e41936. PubMed ID: 22870265
[TBL] [Abstract][Full Text] [Related]
37. Approaches to preventative and therapeutic HIV vaccines.
Gray GE; Laher F; Lazarus E; Ensoli B; Corey L
Curr Opin Virol; 2016 Apr; 17():104-109. PubMed ID: 26985884
[TBL] [Abstract][Full Text] [Related]
38. [Study on Cellular Immune Responses of DNA Vaccine, rAd5 and rMVA Expressing SIV Gag/Env Gene Combined Immunization in Mice].
He X; Chen D; Wang W; Xu K; Zeng Y; Feng X
Bing Du Xue Bao; 2016 Mar; 32(2):170-8. PubMed ID: 27396160
[TBL] [Abstract][Full Text] [Related]
39. Analysis of T cell responses to chimpanzee adenovirus vectors encoding HIV gag-pol-nef antigen.
Herath S; Le Heron A; Colloca S; Bergin P; Patterson S; Weber J; Tatoud R; Dickson G
Vaccine; 2015 Dec; 33(51):7283-7289. PubMed ID: 26546736
[TBL] [Abstract][Full Text] [Related]
40. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.
Malm M; Rollman E; Ustav M; Hinkula J; Krohn K; Wahren B; Blazevic V
Viral Immunol; 2005; 18(4):678-88. PubMed ID: 16359234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
